PET imaging with 11C-dihydotetrabenazine to determine striatal dopamine terminal integrity and with 11C-Pittsburgh compound B to measure cerebral amyloid accumulation can help classify mild cognitive impairment as it develops into Alzheimer's disease, frontotemporal dementia or Lewy body dementia, according to a study published in The Journal of Nuclear Medicine. The dual-target PET technique identified 18 patients with Alzheimer's pathology, seven with FTD characteristics and two with signs of LBD, the study said. Most went on to develop dementia. Having a model for distinguishing between types of MCI could enhance future clinical trials, researchers said.
Published in Brief: